OAB0205	Vesatolimod, a toll-like receptor 7 (TLR7) agonist, induces dose-dependent immune responses in HIV controllers	Oral abstract session with live Q&A	B40
OAB0302	Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1 infection	Oral abstract session with live Q&A	B30
OAB0303	Adherence and factors associated with virologic success in HIV-1 infected adults with tuberculosis receiving raltegravir or efavirenz in the ANRS 12300 Reflate TB2 trial	Oral abstract session with live Q&A	B30
OAB0304	Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation	Oral abstract session with live Q&A	B32
OAB0305	Islatravir safety analysis through week 48 from a phase 2 trial in treatment naïve adults with HIV-1 infection	Oral abstract session with live Q&A	B66
OAB0402	Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon: Week 96 results of the ANRS 12313 ' NAMSAL trial	Oral abstract session with live Q&A	B30
OAB0403	Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results	Oral abstract session with live Q&A	B25
OAB0404	Third-line antiretroviral therapy including raltegravir, darunavir/ritonavir and/or etravirine is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings ACTG: A5288 strategy trial	Oral abstract session with live Q&A	B31
OAB0405	Sub-optimal outcomes with switching to zidovudine vs. recycling tenofovir in second-line treatment in Haiti	Oral abstract session with live Q&A	B30
OAB0502	Efficacy and safety outcomes (HIV subgroup analysis) in the Nix-TB Trial - bedaquiline, pretomanid and linezolid for treatment of extensively resistant, intolerant or non-responsive pulmonary multidrug-resistant tuberculosis	Oral abstract session with live Q&A	B10